Code intelligence

FDA-NDA019625 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-NDA019625.

Normal code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Normal

Critical

High

Routine

100%

Low

New this month

—

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: ELOCON (MOMETASONE FUROATE) — Type 3 - New Dosage Form

Policy FDA-NDA019625 · Dermatology

Routine

Elocon (mometasone furoate) is a topical corticosteroid cream approved under NDA019625, billing through Medicare Part D as a self-administered topical medication. As a long-established brand with exte

View alert

Audit documentation

Building an audit file that includes FDA-NDA019625?

The Tripwire Audit Pack exports 12 months of Dermatology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Dermatology audit pack — $349One-time purchase · not a subscription